Aytu BioPharma (AYTU) 10-Q 11 May 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	9 Months Ended
	Mar. 31, 2023	May 08, 2023
Cover [Abstract]
Entity Central Index Key	0001385818
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-38247
Entity Registrant Name	AYTU BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	373 Inverness Parkway
Entity Address, Address Line Two	Suite 206
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Listing, Par Value Per Share	$ 0.0001
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,780,179
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Current assets
Cash and cash equivalents	$ 19,179	$ 19,360
Accounts receivable, net	34,043	21,712
Inventories	13,637	10,849
Prepaid expenses	10,429	7,375
Other current assets	1,177	633
Total current assets	78,465	59,929
Property and equipment, net	2,028	3,025
Operating lease right-of-use asset	2,367	3,271
Intangible assets, net	63,464	70,632
Other non-current assets	892	766
Total non-current assets	68,751	77,694
Total assets	147,216	137,623
Current liabilities
Accounts payable and other	14,673	10,987
Accrued liabilities	49,585	44,187
Short-term line of credit	10,403	3,813
Current portion of debt	3,305	96
Other current liabilities	7,450	5,359
Total current liabilities	85,416	64,442
Debt, net of current portion	11,386	14,279
Derivative warrant liabilities	1,582	1,796
Other non-current liabilities	7,920	12,798
Total liabilities	106,304	93,315
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of March 31, 2023 and June 30, 2022
Additional paid-in capital	342,584	331,386
Accumulated deficit	(301,672)	(287,078)
Total stockholders' equity	40,912	44,308
Total liabilities and stockholders' equity	$ 147,216	$ 137,623

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	3,779,513	1,928,941
Common stock, shares outstanding (in shares)	3,779,513	1,928,941

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Consolidated Statements of Operations
Product revenue, net	$ 22,733	$ 24,199	$ 76,667	$ 69,221
Revenue from Contract with Customer, Product and Service	Product	Product	Product	Product
Cost of sales	$ 9,990	$ 11,513	$ 28,599	$ 31,780
Gross profit	12,743	12,686	48,068	37,441
Operating expenses
Research and development	856	3,282	3,630	9,409
Selling and marketing	12,804	9,743	33,466	28,700
General and administrative	7,177	7,616	22,517	23,785
Gain from contingent consideration	(734)	(1,234)	(504)	(682)
Impairment expense		45,196	2,600	64,649
Amortization of intangible assets	1,198	1,504	3,593	4,546
Total operating expenses	21,301	66,107	65,302	130,407
Loss from operations	(8,558)	(53,421)	(17,234)	(92,966)
Other income (expense)
Other (expense) income, net	(1,215)	(32)	(3,527)	4
Gain on extinguishment of debt		169		169
Gain (loss) on derivative warrant liabilities	2,573	(7)	6,167	(7)
Total other income (expense)	1,358	130	2,640	166
Loss before income tax	(7,200)	(53,291)	(14,594)	(92,800)
Income tax benefit				(110)
Net loss	$ (7,200)	$ (53,291)	$ (14,594)	$ (92,690)
Weighted average number of common shares outstanding - basic (in shares)	3,726,779	1,484,492	3,099,130	1,360,585
Weighted average number of common shares outstanding - diluted (in shares)	3,726,779	1,484,492	3,099,130	1,360,585
Basic net loss per common share (in dollars per share)	$ (1.93)	$ (35.90)	$ (4.71)	$ (68.13)
Diluted net loss per common share (in dollars per share)	$ (1.93)	$ (35.90)	$ (4.71)	$ (68.13)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Jun. 30, 2021		$ 315,867	$ (178,299)	$ 137,568
Beginning balance (in shares) at Jun. 30, 2021	1,374,520
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,519		1,519
Stock-based compensation (in shares)	11,000
Issuance of common stock, net of issuance costs		270		270
Issuance of common stock, net of issuance costs (in shares)	3,075
Tax withholding for stock-based compensation		(6)		(6)
Net loss			(27,851)	(27,851)
Ending balance at Sep. 30, 2021		317,650	(206,150)	111,500
Ending balance (in shares) at Sep. 30, 2021	1,388,595
Beginning balance at Jun. 30, 2021		315,867	(178,299)	137,568
Beginning balance (in shares) at Jun. 30, 2021	1,374,520
Increase (Decrease) in Stockholders' Equity
Net loss				(92,690)
Ending balance at Mar. 31, 2022		328,737	(270,989)	57,748
Ending balance (in shares) at Mar. 31, 2022	1,667,795
Beginning balance at Sep. 30, 2021		317,650	(206,150)	111,500
Beginning balance (in shares) at Sep. 30, 2021	1,388,595
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,229		1,229
Stock-based compensation (in shares)	3,848
Issuance of common stock, net of issuance costs		4,355		4,355
Issuance of common stock, net of issuance costs (in shares)	108,079
Net loss			(11,548)	(11,548)
Ending balance at Dec. 31, 2021		323,234	(217,698)	105,536
Ending balance (in shares) at Dec. 31, 2021	1,500,522
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,270		1,270
Stock-based compensation (in shares)	5,388
Issuance of common stock, net of issuance costs		3,856		3,856
Issuance of common stock, net of issuance costs (in shares)	161,885
Tax withholding for stock-based compensation		(2)		(2)
Warrants issued with debt refinance		379		379
Net loss			(53,291)	(53,291)
Ending balance at Mar. 31, 2022		328,737	(270,989)	57,748
Ending balance (in shares) at Mar. 31, 2022	1,667,795
Beginning balance at Jun. 30, 2022		331,386	(287,078)	$ 44,308
Beginning balance (in shares) at Jun. 30, 2022	1,928,941			1,928,941
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,177		$ 1,177
Stock-based compensation (in shares)	(1,666)
Issuance of common stock, net of issuance costs		3,564		3,564
Issuance of common stock, net of issuance costs (in shares)	1,194,196
Net loss			(701)	(701)
Ending balance at Sep. 30, 2022		336,127	(287,779)	48,348
Ending balance (in shares) at Sep. 30, 2022	3,121,471
Beginning balance at Jun. 30, 2022		331,386	(287,078)	$ 44,308
Beginning balance (in shares) at Jun. 30, 2022	1,928,941			1,928,941
Increase (Decrease) in Stockholders' Equity
Net loss				$ (14,594)
Ending balance at Mar. 31, 2023		342,584	(301,672)	$ 40,912
Ending balance (in shares) at Mar. 31, 2023	3,779,513			3,779,513
Beginning balance at Sep. 30, 2022		336,127	(287,779)	$ 48,348
Beginning balance (in shares) at Sep. 30, 2022	3,121,471
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		3,067		3,067
Stock-based compensation (in shares)	(19,228)
Issuance of common stock, net of issuance costs		1,095		1,095
Issuance of common stock, net of issuance costs (in shares)	280,902
Net loss			(6,693)	(6,693)
Ending balance at Dec. 31, 2022		340,289	(294,472)	45,817
Ending balance (in shares) at Dec. 31, 2022	3,383,145
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		902		902
Stock-based compensation (in shares)	8,747
Issuance of common stock, net of issuance costs		1,393		1,393
Issuance of common stock, net of issuance costs (in shares)	387,621
Net loss			(7,200)	(7,200)
Ending balance at Mar. 31, 2023		$ 342,584	$ (301,672)	$ 40,912
Ending balance (in shares) at Mar. 31, 2023	3,779,513			3,779,513

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities
Net loss	$ (14,594)	$ (92,690)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	6,699	7,926
Impairment expense	2,600	64,649
Stock-based compensation expense	5,146	4,018
(Gain) loss on derivative warrant liabilities	(6,167)	7
Gain from contingent consideration	(504)	(682)
Amortization of senior debt (premium) discount	413	(268)
(Gain) on sale of equipment	(42)	(44)
Gain on extinguishment of debt		(193)
Inventory write-down	199	352
Other noncash adjustments	13	(152)
Changes in operating assets and liabilities:
Accounts receivable	(12,335)	647
Inventories	(2,987)	91
Prepaid expenses and other current assets	(3,603)	1,406
Accounts payable and other	3,720	(8,099)
Accrued liabilities	7,031	1,252
Other operating assets and liabilities, net	(83)	52
Net cash used in operating activities	(14,494)	(21,728)
Investing Activities
Contingent consideration payment		(3,138)
Other investing activities	38	(69)
Net cash provided by (used in) investing activities	38	(3,207)
Financing Activities
Proceeds from issuance of stock and warrants	13,012	12,700
Payment of stock issuance costs	(1,045)	(782)
Payment made to fixed payment arrangement	(4,117)	(3,277)
Payments made to borrowings	(73)	(16,075)
Proceeds from borrowings		15,000
Payment for debt issuance costs	(92)	(363)
Net proceeds received (payments made on) short-term line of credit	6,590	(4,549)
Other financing activities		(7)
Net cash provided by financing activities	14,275	2,647
Net change in cash, cash equivalents and restricted cash	(181)	(22,288)
Cash, cash equivalents and restricted cash at beginning of period	19,360	49,901
Cash and cash equivalents at end of period	19,179	27,613
Supplemental cash flow data
Cash paid for interest	$ 2,861	3,080
Non-cash investing and financing activities:
Other noncash investing and financing activities		$ 473

Nature of Business, Financial C

Nature of Business, Financial Condition, Basis of Presentation	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business, Financial Condition, Basis of Presentation	1. Nature of Business, Financial Condition, Basis of Presentation Aytu BioPharma, Inc. (“Aytu”, the “Company” or “we”), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through two business segments (i) the Rx segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health segment, which consists of various consumer healthcare products (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc. On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty The Rx segment primarily consists of two product portfolios: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”) together the “ADHD Portfolio”, and the “Pediatric Portfolio” consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions. The Consumer Health Portfolio consists of over twenty consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. The Company’s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team’s expertise to build leading brands within large therapeutic and consumer health markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has indefinitely suspended active development of its clinical development programs including AR101 (enzastaurin), Healight, and NT0502 (N-desethyloxybutynin). As of March 31, 2023, the Company had approximately $19.2 million of cash and cash equivalents and approximately $34.0 million in accounts receivable. The Company’s operations have historically consumed cash and are expected to continue to consume cash. The Company incurred a net loss of $7.2 million and $14.6 million during the three and nine months ended March 31, 2023, respectively. The Company had an accumulated deficit of $301.7 million as of March 31, 2023. Cash used in operations was $14.5 million during the nine months ended March 31, 2023. During the nine months ended March 31, 2023, the Company issued 699,929 shares of common stock under the “At-The-Market” (“ATM”) (see Note — 14 Capital Structure) for total gross proceeds of approximately $3.0 million before deducting commissions of 3% and other offering expenses including legal and audit fees. The Company intends to use the net proceeds from the Offering and from the ATM for growth of the Company’s commercial business, and for working capital and general corporate purposes. As of March 31, 2023, the Company did not have sufficient working capital to cover its cash needs to fund planned operations for the twelve months following the filing date of this Quarterly Report on Form 10-Q, which raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management plans to continue to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern, primarily by focusing on increasing revenue, reducing expenses associated with research and development, and raising additional capital through public or private equity, debt offerings, or monetizing assets in order to meet its obligations. Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities and continue the suspension of its developmental programs or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern. Basis of Presentation. Also see Note 2 – Previously Reported Financial Statements relating to the immaterial correction of an error in the condensed consolidated financial statements for as of June 30, 2022, and for the three and nine months ended March 31, 2022. Prior Period Reclassification ​ ​

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, the value of goodwill, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Previously Reported Financial Statements The classification of certain of the Company’s warrants was previously recorded as equity. These warrants according to Generally Accepted Accounting Principles in the United States (“GAAP”) should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the quarterly unaudited financial statements as of March 31, 2022 and the audited financial statements as of June 30, 2022. ​ SEC Staff Accounting Bulletin No. 99, “Materiality,” and the Financial Accounting Standards Board (“FASB”), Statement of Financial Accounting Concepts No. 2 “Qualitative Characteristics of Accounting Information” indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the condensed consolidated financial statements for the quarter ended March 31, 2022 and to the condensed consolidated balance sheet as of June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to these periods for comparative purposes. The adjustments did not change the Company’s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations. ​ The condensed consolidated financial statements as of and for the three and nine months ended March 31, 2022 have been adjusted as shown in the following tables. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liabilities ​ $ 211 ​ $ (218) ​ $ (7) Total other (expense) income ​ $ 348 ​ $ (218) ​ $ 130 Loss before income tax ​ $ (53,073) ​ $ (218) ​ $ (53,291) Net loss ​ $ (53,073) ​ $ (218) ​ $ (53,291) Basic and diluted net loss per common share ​ $ (35.80) ​ $ (0.10) ​ $ (35.90) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Issuance of common stock, net of issuance cost ​ $ 7,034 ​ $ (3,178) ​ $ 3,856 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss by segment ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment ​ $ (52,311) ​ $ (218) ​ $ (52,529) Consumer Health Segment ​ ​ (762) ​ ​ — ​ ​ (762) Consolidated net loss ​ $ (53,073) ​ $ (218) ​ $ (53,291) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liabilities ​ $ 211 ​ $ (218) ​ $ (7) Total other (expense) income ​ $ 384 ​ $ (218) ​ $ 166 Loss before income tax ​ $ (92,582) ​ $ (218) ​ $ (92,800) Net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) Basic and diluted net loss per common share ​ $ (68.00) ​ $ (0.13) ​ $ (68.13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flow data ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) Gain on derivative warrant liabilities ​ $ (211) ​ $ 218 ​ $ 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss by segment ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment ​ $ (88,359) ​ $ (218) ​ $ (88,577) Consumer Health Segment ​ ​ (4,113) ​ ​ — ​ ​ (4,113) Consolidated net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional paid-in capital ​ $ 331,915 ​ $ (3,178) ​ $ 328,737 Accumulated deficit ​ ​ (270,771) ​ ​ (218) ​ ​ (270,989) Total stockholders’ equity ​ $ 61,144 ​ $ (3,396) ​ $ 57,748 ​ The consolidated balance sheet and the consolidated statement of stockholders’ equity as of June 30, 2022 have been adjusted as shown in the table below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Derivative warrant liabilities ​ $ — ​ $ 1,796 ​ $ 1,796 Total liabilities ​ $ 91,531 ​ $ 1,784 ​ $ 93,315 Additional paid-in capital ​ $ 334,560 ​ $ (3,174) ​ $ 331,386 Accumulated deficit ​ $ (288,472) ​ $ 1,394 ​ $ (287,078) Total stockholders’ equity ​ $ 46,092 ​ $ (1,784) ​ $ 44,308 ​ Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable. Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and nine months ended March 31, 2023. An ownership change (generally a 50% change in equity ownership over a three-year period) could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. The Company believes that previous acquisitions, financing transactions, and equity ownership changes in the past five years may have caused a limitation on its ability to use the pre-acquisition net operating loss carryovers. The ownership change scenario could result in increased future tax liability. The Company is in the process of analyzing the impact of any possible ownership change result of which may be a change to the Company’s net deferred tax asset or liability position. Impairment of Other Intangibles Assets Acquired in-process research and development (“IPR&D) is an intangible asset classified as an indefinite-lived asset until the completion or abandonment of the associated research and development (“R&D”) effort. In periods after the acquisition of IPR&D, the Company may (1) continue internal R&D efforts associated with the acquired assets or collaborate with another party in R&D efforts; (2) dispose of the assets through a sale; (3) out-license the assets; (4) temporarily postpone further development; or (5) abandon R&D efforts. IPR&D may be subject to different subsequent accounting treatment depending on the course of action chosen by the Company with respect to the asset. If the Company changes strategies related to the IPR&D the asset could potentially be impaired (see Note —7 Goodwill and Other Intangible Assets). Recent Adopted Accounting Pronouncements Reference Rate Reform. , Reference Rate Reform (Topic 848): “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” Earnings Per Share. In May 2021, the FASB issued ASU 2021-04, “ Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ”. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on its condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” anticipate the application of ASU 2016-13 will have a material impact on the Company’s condensed consolidated financial position or results of operations. For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. There have been no significant changes to the Company’s significant accounting policies during the nine months ended March 31, 2023.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	9 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	3. Revenues from Contracts with Customers Net product sales in the BioPharma Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer which typically aligns with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. The Company generates Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, as those are the agreed-upon contractual terms and align with the transfer of control. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales. ​ Savings offers, rebates and wholesaler chargebacks ​ Revenues by Segment. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 ​ ​ (In thousands) ​ Rx Segment ​ $ 13,805 ​ $ 13,862 ​ $ 50,486 ​ $ 42,388 ​ Consumer Health Segment ​ ​ 8,928 ​ ​ 10,337 ​ ​ 26,181 ​ ​ 26,833 ​ Consolidated revenue $ 22,733 $ 24,199 $ 76,667 $ 69,221 ​ Revenues by Geographic location .

Inventories

Inventories	9 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred $0.1 million and $2.0 million for the three months ended March 31, 2023 and 2022, respectively; and $0.2 million and $2.4 million for the nine months ended March 31, 2023 and 2022, respectively. Inventory balances consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ (In thousands) Raw materials $ 2,223 $ 1,814 Work in process ​ ​ 2,817 ​ ​ 1,838 Finished goods ​ 8,597 ​ 7,197 Inventory ​ $ 13,637 ​ $ 10,849

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,449 $ 2,487 Leasehold improvements 1,003 ​ 999 Office equipment, furniture and other 1,128 ​ 1,128 Lab equipment 832 ​ 832 Property and equipment, gross ​ ​ 5,412 ​ ​ 5,446 Less accumulated depreciation and amortization ​ ​ (3,384) ​ ​ (2,421) Property and equipment, net $ 2,028 ​ $ 3,025 ​ ​ Depreciation and amortization expense was $0.3 million and $0.5 million for the three months ended March 31, 2023 and 2022, respectively; and $1.0 million and $1.3 million for the nine months ended March 31, 2023 and 2022, respectively.

Leases

Leases	9 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	6. Leases The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between fiscal years 2023 and 2027. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. The components of lease expenses are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ ​ March 31, ​ March 31, ​ ​ ​ 2023 2022 2023 2022 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 360 ​ $ 316 ​ $ 1,076 ​ $ 942 Operating expenses Short-term lease cost 27 ​ 65 71 ​ 130 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets 14 ​ 18 51 ​ 55 Cost of sales Interest on lease liabilities ​ ​ 2 ​ ​ 3 ​ ​ 7 ​ ​ 11 ​ Other (expense), net Total net lease cost $ 403 ​ $ 402 $ 1,205 ​ $ 1,138 ​ ​ Supplemental balance sheet information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, Balance Sheet Classification ​ ​ 2023 ​ 2022 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 2,367 ​ $ 3,271 Operating lease right-of-use asset Finance lease assets ​ ​ 174 ​ 256 Property and equipment, net Total leased assets ​ $ 2,541 ​ $ 3,527 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,252 ​ $ 1,227 ​ Other current liabilities Finance leases ​ ​ 91 ​ ​ 96 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 1,154 ​ ​ 2,090 ​ Other non-current liabilities Finance leases ​ ​ 15 ​ ​ 84 ​ Debt, net of current portion Total lease liabilities ​ $ 2,512 ​ $ 3,497 ​ ​ ​ ​ Remaining lease term and discount rate used are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 1.94 ​ ​ 2.63 ​ Finance lease assets ​ 1.12 ​ ​ 1.73 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.68 % ​ 7.48 % Finance lease assets ​ ​ 6.54 % ​ 6.43 % ​ ​ Supplemental cash flow information related to lease is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, ​ 2023 2022 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows - operating leases ​ $ 1,076 ​ $ 942 Operating cash flows - finance leases ​ $ 7 ​ $ 12 Financing cash flows - finance leases ​ $ 73 ​ $ 76 ​ ​ As of March 31, 2023, the maturities of the Company’s future minimum lease payments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 360 ​ $ 23 2024 ​ ​ 1,379 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 2,624 ​ ​ 110 Less: Imputed interest ​ ​ (218) ​ ​ (4) Lease liabilities ​ $ 2,406 ​ $ 106 ​

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	7. Goodwill and Other Intangible Assets The Company’s strategy is to continue building its portfolio of revenue-generating products by leveraging its commercial team’s expertise to build leading brands within large therapeutic and consumer health markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has decided to abandon active development of its NT0502 (N-desethyloxybutynin), a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. During the nine months ended March 31, 2023, the Company incurred an impairment charge of $2.6 million related to NT0502. The Company has terminated the licensing agreement. The Company has also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. The following table provides the summary of the Company’s intangible assets as of March 31, 2023 and June 30, 2022, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ ​ 45,400 ​ ​ (10,077) ​ ​ (3,224) ​ ​ 32,099 11.55 Acquired technology right ​ ​ 30,200 ​ ​ (3,610) ​ ​ — ​ ​ 26,590 ​ 15.00 Acquired product distribution rights ​ 11,354 ​ (4,407) ​ (2,172) ​ 4,775 6.85 ​ ​ ​ 86,954 ​ ​ (18,094) ​ ​ (5,396) ​ ​ 63,464 ​ 12.64 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 89,554 ​ $ (18,094) ​ $ (7,996) ​ $ 63,464 12.64 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 45,400 ​ $ (7,667) ​ $ (3,224) ​ $ 34,509 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ 11,354 ​ (3,581) ​ (2,172) ​ 5,601 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 13.35 ​ ​ ​ The following table summarizes the estimated future amortization expense to be recognized over the next five years and periods thereafter: ​ ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 1,518 2024 ​ ​ 6,074 2025 ​ ​ 5,934 2026 ​ ​ 5,683 2027 ​ ​ 5,653 2028 ​ ​ 5,553 Thereafter ​ ​ 33,049 Total future amortization expense ​ $ 63,464 ​ ​ Acquired Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal ER. Poly-Vi-Flor and Tri-Vi-Flor. ADHD Portfolio. Acquired Technology Right TRRP Technology. Acquired Product Distribution Rights (and Customer List) In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. Acquired In-Process R&D IPR&D – NT0502 Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.5 million and $2.0 million for the three months ended March 31, 2023 and 2022, respectively; and $4.6 million and $6.1 million during the nine months ended March 31, 2023 and 2022, respectively.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Mar. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	8. Accrued liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Accrued savings offers ​ $ 18,370 ​ $ 12,711 Accrued program liabilities ​ ​ 10,287 ​ ​ 9,468 Accrued customer and product related fees ​ ​ 6,379 ​ ​ 7,817 Product return reserve ​ 4,708 ​ 5,770 Accrued employee compensation ​ ​ 6,864 ​ ​ 4,765 Other accrued liabilities ​ ​ 2,977 ​ ​ 3,656 Total accrued liabilities ​ $ 49,585 ​ $ 44,187 ​ ​ Savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. ​ Program liabilities include government rebates. ​ Customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. ​ Accrued employee compensation includes sales commissions, vacation earned, and accrued payroll. ​ Other accrued liabilities consist of accrued license fees, legal settlements, professional fees, credit card liabilities, taxes payable, and samples expense .

Other Liabilities

Other Liabilities	9 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities	9. Other Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangements ​ $ 10,678 ​ $ 13,051 Operating lease liabilities ​ 2,406 ​ 3,317 Contingent value rights ​ ​ 465 ​ ​ 578 Contingent consideration ​ ​ — ​ ​ 396 Other ​ ​ 1,821 ​ ​ 815 Total other liabilities ​ ​ 15,370 ​ ​ 18,157 Less: current portion ​ ​ (7,450) ​ ​ (5,359) Total other liabilities, noncurrent ​ $ 7,920 ​ $ 12,798 ​ ​ Fixed Payment Arrangements. Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. These obligations included fixed monthly payments equal to $0.1 million from November 2019 through January 2021 plus $15.0 million due in January 2021, of which $15.0 million was paid down in May 2020. Monthly variable payments due to the same investor are equal to 15.0% of net revenue generated from a subset of the Pediatric Portfolio, subject to an aggregate monthly minimum of $0.1 million, except for January 2021, when a one-time payment of $0.2 million was due and paid. The variable payment obligation was to continue until the earlier of (i) aggregate variable payments of approximately $9.3 million have been made or (ii) February 12, 2026. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in partial satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted for the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023. ​ The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of March 31, 2023, the fixed payment arrangement balance was $1.7 million in other current liabilities and $2.6 million in other non-current liabilities on the condensed consolidated balance sheet. ​ On May 12, 2022, the Company entered into an agreement with Tris to terminate the Tuzistra XR License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced our total liability for minimum payments by approximately $8.0 million from the original License Agreement. As of March 31, 2023, the balance was $4.0 million in other current liabilities and $2.4 million in other non-current liabilities on the condensed consolidated balance sheet. Pursuant to the settlement agreement, if the Company does not make timely payments, it is required to pay interest on any outstanding balances at the greater of 2.5% per month and the maximum interest rate permitted by law. Contingent Value Rights. ​ Contingent value rights (“CVRs”) represent contingent consideration related to the Company’s 2020 acquisition of Innovus of up to $16.0 million payable upon attainment of future performance milestones. Consideration can be satisfied in up to 470,000 shares of the Company’s common stock, or cash either upon the option of the Company or in the event there are insufficient shares available to satisfy such obligations. As of March 31, 2023, up to $5.0 million of future milestone payments potentially remain. As of March 31, 2023 and June 30, 2022, the CVRs were valued at $0.5 million and $0.6 million, respectively. ​ Contingent Consideration . Contingent consideration represents the fair value of potential future payments in connection with acquisitions that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Subsequent changes in the fair value of contingent consideration obligations are recognized in the condensed consolidated statements of income. In connection with the Company’s 2020 acquisition of Innovus, the Company recognized approximately $0.2 million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. As of March 31, 2023 and June 30, 2022, the contingent consideration balance was zero and $0.4 million, respectively. Through March 31, 2022, the Company’s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR . The royalty and make-whole milestone payments related to licensing agreements with Tris for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra XR and the settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris for termination of the Tuzistra XR licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company’s estimated borrowing rate. Through March 31, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (“Magna”) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. During the three months ended March 31, 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Magna licensing agreements in other current liabilities. Other. Other consist of taxes payable and deferred cost related to our technology transfer.

Line of Credit

Line of Credit	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Line of Credit	10. Line of Credit Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the “Revolving Loans”), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued at variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022. In connection with the Avenue Capital Agreement, described in Note 11— Long-term debt below, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the “Eclipse Second Amendment”). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment. On March 24, 2023, the Company and certain of its subsidiaries entered into an Amendment No. 4 (the Eclipse Amendment”) to the Loan and Security Agreement dated October 2, 2019 (as amended by Amendment No. 1, dated March 19, 2021, Amendment No. 2, dated January 26, 2022, Amendment No. 3, dated June 1, 2022, and the Eclipse Amendment (the “Eclipse Agreement”). The Eclipse Amendment, among other things, provided for an aggregate increase of $2.0 million to the Eclipse Lender’s commitment to make revolving loans from time to time under the Eclipse Agreement and increased the maximum amount available under the revolving credit facility provided under the Eclipse Agreement to $14.5 million. The Company paid $10,000 in fees associated to the Eclipse Amendment. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement at any time with at least five business days prior notice to Eclipse. The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of March 31, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement. The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $0.2 million and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. For the nine months ended March 31, 2023 and 2022, interest expense was $0.5 million and $0.4 million, respectively.

Long-term Debt

Long-term Debt	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Long-term Debt	11. Long-term Debt Avenue Capital Loan: On January 26, 2022 (“Closing Date”), the Company entered into a Loan and Security Agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund, L.P.(“Avenue”) and Avenue Venture Opportunities Fund II, L.P. (Avenue 2”) as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”), (collectively “Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate and 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used to repay the Deerfield Facility. Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided, as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period could further be extended automatically without any action by any party for an additional twelve months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue (“Interest-only Milestone 2”) as of the date of determination. In connection with the Eclipse Amendment, on March 24, 2023, Avenue amended certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022). The Avenue amendment, among other things, permitted the increase in revolving loan commitment provided by the Eclipse Lender under the Eclipse Facility. In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement. The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of March 31, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement. On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027. The Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was not fixed at the Issuance Date. On On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (“Avenue”) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing. In addition to the debt discounts discussed above, the Company also incurred $0.4 million in loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 15.37%. Total interest expense, including debt discount amortization, was $0.7 million and $0.4 million for the three months ended March 31, 2023 and 2022, respectively; and $2.0 million and $0.4 million for the nine months ended March 31, 2023 and 2022, respectively. Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 ​ ​ 638 Unamortized discount and issuance costs ​ ​ (1,053) ​ ​ (1,443) Financing leases, maturing through May 2024 ​ ​ 106 ​ ​ 180 Total debt ​ ​ 14,691 ​ ​ 14,375 Less: current portion ​ ​ (3,305) ​ ​ (96) Non-current portion of debt ​ $ 11,386 ​ $ 14,279 ​ Future principal payments of long-term debt, including financing leases, are as follows: ​ ​ ​ ​ ​ ​ March 31, ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 91 2024 ​ ​ 3,230 2025 ​ ​ 12,423 Future principal payments ​ ​ 15,744 Less unamortized discount and issuance costs ​ ​ (1,053) Less current portion ​ ​ (3,305) Non-current portion of debt ​ $ 11,386 ​

Fair Value Considerations

Fair Value Considerations	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Considerations	12. Fair Value Considerations We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows: ● Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; ● Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and ● Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our condensed consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. Recurring Fair Value Measurements The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2023 and June 30, 2022, by level within the fair value hierarchy. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at March 31, 2023 ​ Fair Value at March 31, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration $ — $ — $ — $ — CVR liability ​ 465 ​ — ​ — ​ 465 Derivative warrant liabilities ​ ​ 1,582 ​ — ​ — ​ 1,582 Total ​ $ 2,047 $ — $ — ​ $ 2,047 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 396 $ — $ — $ 396 CVR liability ​ ​ 578 ​ — ​ — ​ 578 Derivative warrant liabilities ​ ​ 1,796 ​ ​ — ​ ​ — ​ ​ 1,796 Total ​ $ 2,770 $ — $ — ​ $ 2,770 ​ ​ Summary of Level 3 Input Changes The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the nine months ended March 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent ​ ​ Derivative ​ Fixed Payment ​ ​ Liability ​ Consideration ​ ​ Warrant Liabilities ​ Arrangement ​ ​ (In thousands) Balance as of June 30, 2022 $ 578 ​ $ 396 ​ $ 1,796 ​ $ 13,051 Included in earnings ​ (113) ​ ​ (391) ​ ​ (6,167) ​ ​ 1,202 Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ ​ ​ ​ Issues — ​ — ​ 5,953 ​ — Settlements — ​ (5) ​ — ​ (3,575) Balance as of March 31, 2023 $ 465 ​ $ — ​ $ 1,582 ​ $ 10,678 ​ Significant Assumptions Significant assumptions used in valuing CVRs were as follows: ​ ​ ​ ​ ​ ​ March 31, ​ 2023 Leveraged Beta 0.82 ​ Market risk premium ​ 6.35 % Risk-free interest rate ​ 4.79 % Discount ​ 21.25 % Company specific discount 10.00 % ​ ​ ​ Significant assumptions used in valuing ​ ​ ​ ​ ​ ​ August 9, ​ 2022 Expected volatility 89.89 % Equivalent term (years) ​ 4.11 ​ Risk-free rate ​ 3.09 % Dividend yield ​ 0.00 % ​ valuing ​ ​ ​ ​ ​ ​ March 31, ​ 2023 Expected volatility 75.51 % Equivalent term (years) ​ 3.84 - 4.44 ​ Risk-free rate ​ 3.65 - 3.73 % Dividend yield ​ 0.00 % ​ ​ The fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their ultimate face value over time.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Pediatric Portfolio Fixed Payments and Product Milestone The Company has two fixed, periodic payment obligations to an investor (the “Fixed Obligation”). Under the first fixed obligation, the Company was to make monthly payments of $0.1 million beginning November 1, 2019 through January 2021, with a balloon payment of $15.0 million that was originally due in January 2021 (“Balloon Payment Obligation”). A second fixed obligation required the Company to pay a minimum of $0.1 million monthly through February 2026, except for $0.2 million paid in January 2020. On May 29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the “Early Payment Agreement”) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the six quarters commencing September 30, 2021. The outstanding balance for the Waiver, Release and Consent obligation as of December 31, 2022 was paid in January 2023. The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. Rumpus Earn Out Payments On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, we made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones we may be required to pay up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. Legal Proceeding Aponowicz and Paguia Class-Action Securities Litigations. ​

Capital Structure

Capital Structure	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Capital Structure	14. Capital Structure The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. Included in the common stock outstanding are 48,818 shares of unvested restricted stock issued to executives, directors and employees. On June 8, 2020, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2020 Shelf”). As of March 31, 2023, approximately $40.4 million remains available under the 2020 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. On June 4, 2021, the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the nine months ended March 31, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. As of March 31, 2023, the Company had approximately $2.0 million of capacity under the ATM Sales Agreement due to baby self-limitations. As our market capitalization increases, these limitations will be adjusted and the Company will be able to issue additional ATM sales. On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of March 31, 2023, approximately $82.4 million remained available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. On August 11, 2022, the Company closed on an underwritten public offering (the “August 2022 Offering”), pursuant to which we sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 87,500 shares of its common stock, and (iii) accompanying warrants (the "Common Warrants") to purchase 1,265,547 shares of its common stock. The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase one share of common stock for each share of common stock or each Pre-Funded Warrant sold. The combined public offering price for each share of common stock and accompanying Common Warrant was $8.60, and the combined offering price for each Pre-Funded Warrant and accompanying Common Warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying Common Warrant, less the $0.001 per share exercise price of each Pre-Funded Warrant. The Pre-Funded Warrants were exercised in full in August 2022. The Common Warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The Pre-Funded and Common Warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities in the Company’s financial statements. (See Note 16 – Warrants).

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	15. Equity Incentive Plans Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”), which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the Aytu 2015 Plan. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years . The restricted stock awards have a vesting period ranging from 4 to 10 years , whereas the restricted stock units have a vesting period of 4 years . As of March 31, 2023, the Company had 84,554 shares that are available for grant under the Aytu 2015 Plan. Neos 2015 Plan. Stock Options Stock option activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 3,899 ​ $ 209.70 7.77 Granted 49,212 ​ ​ 4.00 Forfeited/Cancelled (152) ​ ​ 126.84 Expired (175) ​ ​ 131.45 Outstanding at March 31, 2023 52,784 ​ $ 18.42 9.31 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at March 31, 2023 2,920 ​ $ 227.28 6.44 ​ ​ As of March 31, 2023, there was $0.2 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.7 years. Restricted Stock During the nine months ended March 31, 2023, as a result of the change in members of the Company’s board, the Company accelerated unvested shares for two former members and recorded $1.5 million of non-cash equity compensation expense. On December 19, 2022, the Company entered into a Stipulation of Compromise and Settlement (the “Stipulation”). As a part of the terms of the Stipulation, the Company agreed to rescind 25% of the aggregate 2021 grants to board members. As a result of the recission of the shares, the Company recorded $0.6 million in non-cash compensation Restricted stock activity under the Aytu 2015 Plan is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 80,373 ​ $ 148.91 Granted 6,825 ​ ​ 3.79 Vested (36,695) ​ ​ 135.41 Forfeited/Cancelled ​ (6,689) ​ ​ 135.66 Unvested at March 31, 2023 43,814 ​ $ 139.63 ​ ​ As of March 31, 2023, there was $4.9 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.4 years. The Company previously issued 4 shares of restricted stock outside the Aytu 2015 Plan, which vest in July 2026. On January 17, 2022, the Company granted 5,000 shares of restricted stock to team outside of the Aytu 2015 Plan. As of March 31, 2023, there was total Restricted Stock Units RSUs activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 8,500 ​ $ 25.88 Vested (2,580) ​ ​ 26.85 Unvested at March 31, 2023 5,920 ​ $ 25.42 ​ ​ As of March 31, 2023, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9 years. Stock-based compensation expense related to the fair value of stock options and restricted stock and RSUs was included in the condensed consolidated statements of operations as set forth in the below table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2023 2022 ​ 2023 2022 ​ ​ (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales ​ $ 4 ​ $ 7 ​ $ 12 ​ $ 24 Research and development ​ ​ 2 ​ ​ 73 ​ ​ 25 ​ ​ 467 Selling and marketing ​ ​ 3 ​ ​ 23 ​ ​ 9 ​ ​ 51 General and administrative ​ 893 ​ 1,167 ​ 5,100 ​ 3,476 Total stock-based compensation expense ​ $ 902 ​ $ 1,270 ​ $ 5,146 ​ $ 4,018

Warrants

Warrants	9 Months Ended
	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Warrants	16. Warrants Liability Classified Warrants On August 11, 2022, the Company closed on the August 2022 Offering, pursuant to which, the Company issued Pre-Funded Warrants to purchase 87,500 shares of its common stock and Common Warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, which one Common Warrant to purchase one share of common stock for each share of common stock or each Pre-Funded Warrant sold. The Pre-Funded Warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The Common Warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Common Warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the Common Stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The Common Warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 – Capital Structure). In November and throughout the quarter end the Company sold shares through its ATM Sales Agreement. Per the warrant agreement, these sales qualified as an equity offering and the sales price was less than the current the exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a 20 On October 25, 2022, the Company entered into an agreement with Avenue to extend the interest-only period of the Company’s existing senior secured loan facility. The amendment to the original secured loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s latest equity financing. ​ Outstanding warrants are classified as derivative warrant liabilities in the condensed consolidated balance sheets and are marked to market at each reporting period (see Note 12 – Fair Value Considerations). A summary of warrants is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 433,174 ​ $ 92.60 4.73 Warrants issued 1,353,047 ​ 3.28 5.00 Warrants exercised ​ (87,500) ​ ​ 0.02 ​ 5.00 Warrants expired (17,414) ​ 1,200.77 — Outstanding March 31, 2023 1,681,307 ​ $ 13.41 4.30

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Common Share	17. Net Loss per Common Share Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. The following table sets forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ 2023 2022 Warrants to purchase common stock - liability classified ​ ​ 1,642,235 377,893 Warrant to purchase common stock - equity classified ​ ​ 39,072 56,486 Employee stock options ​ ​ 52,784 4,193 Employee unvested restricted stock ​ ​ 48,818 106,874 Employee unvested restricted stock units ​ ​ ​ 5,920 ​ 7,724 Total ​ ​ ​ 1,788,829 553,170

License Agreements

License Agreements	9 Months Ended
	Mar. 31, 2023
License Agreement [Abstract]
Licensing Agreements	18. License Agreements Healight In April 2020, we entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight. The agreement with Cedars-Sinai grants us a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. As a result of the focus on revenue growth of our commercial business we have terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023. NeuRx In October 2018, Neos entered into an Exclusive License Agreement (“NeuRx License”) with NeuRx Pharmaceuticals LLC (“NeuRx”), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx’s proprietary compound designated as NRX-101, referred to as NT0502. NT0502 is a new chemical entity that is being developed for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i) the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii) expiration of regulatory exclusivity of such licensed product in such country. In April 2023, the Company returned the NT0502 rights to NeuRx in exchange for and receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on NT0502. Teva On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. Actavis On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis (now Teva, following Teva’s acquisition of Actavis’ generic products) has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. Shire In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the “2014 License Agreement”) with Shire LLC (“Shire”) for a non-exclusive license to certain patents for certain activities with respect to Neos’ New Drug Application (the “NDA”) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. The settlement agreement expires May of 2023. In March 2017, Neos entered into a License Agreement (the “2017 License Agreement”) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos’ NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos was paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021. The royalties are recorded as cost of sales in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents. ​

Segment Reporting

Segment Reporting	9 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	19. Segment Reporting The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx segment consists of the Company’s prescription products. The Consumer Health segment contains the Company’s consumer healthcare products. Select financial information for these segments is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2023 2022 ​ 2023 2022 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ ​ ​ ​ Rx Segment ​ $ 13,805 ​ $ 13,862 ​ $ 50,486 ​ $ 42,388 Consumer Health Segment ​ 8,928 ​ 10,337 ​ 26,181 ​ 26,833 Consolidated revenue ​ $ 22,733 ​ $ 24,199 ​ $ 76,667 ​ $ 69,221 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated net loss: ​ ​ ​ ​ Rx Segment ​ $ (5,777) ​ $ (52,529) ​ $ (10,931) ​ $ (88,577) Consumer Health Segment ​ (1,423) ​ (762) ​ (3,663) ​ (4,113) Consolidated net loss ​ $ (7,200) ​ $ (53,291) ​ $ (14,594) ​ $ (92,690) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Total assets: ​ ​ ​ ​ ​ ​ Rx Segment ​ $ 131,982 ​ $ 121,377 Consumer Health Segment ​ 15,234 ​ 16,246 Consolidated assets ​ $ 147,216 ​ $ 137,623 ​

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events ​ Sublease a portion of Grand Prairie Facility On April 27, 2023, the Company entered into an agreement with AMT Manufacturing Solutions, LLC (“AMTMS”) to sublease 22,909 square feet of its manufacturing facility in Grand Prairie, Texas (“Sublease Agreement”). The Sublease Agreement is subject and subordinate to that certain Commercial Lease Agreement by and between the Company, as successor-in-interest to PharmaFab, Inc., as tenant, and Riverside Business Green, LP, as Landlord, as successor-in-interest to Walstib, L.P., as landlord, dated June 29, 1999, as amended, and expiring on December 31, 2024. The sublease will commence on May 15, 2023. The expansion date (“Expansion Date”) will commence as early as April 1, 2024 but no later than December 31, 2024, which date shall be designated by the Company by written notice to AMTMS not less than thirty (30) days prior to the Expansion Date. The subleased property shall be expanded to include the remaining 54,203 square feet of the Company’s manufacturing facility. The Sublease Agreement will terminate on December 31, 2024. Under the terms of the Sublease Agreement, AMTMS will pay the Company base rent of $20,045 per month through December 31, 2023 and $21,000 per month from January 1, 2024 through the Expansion Date. Beginning on the Expansion Date, base rent will be $70,686 per month through the expiration of the Sublease Agreement. In addition to the base rent, AMTMS will pay the Company certain operating expenses incurred by the Company. AMTMS will pay a security deposit of $90,731 to the Company which will be applied to rent payments if certain conditions are met. ​

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation. Also see Note 2 – Previously Reported Financial Statements relating to the immaterial correction of an error in the condensed consolidated financial statements for as of June 30, 2022, and for the three and nine months ended March 31, 2022.
Prior Period Reclassification	Prior Period Reclassification ​
Use of Estimates	Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, the value of goodwill, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Previously Reported Financial Statements	Previously Reported Financial Statements The classification of certain of the Company’s warrants was previously recorded as equity. These warrants according to Generally Accepted Accounting Principles in the United States (“GAAP”) should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the quarterly unaudited financial statements as of March 31, 2022 and the audited financial statements as of June 30, 2022. ​ SEC Staff Accounting Bulletin No. 99, “Materiality,” and the Financial Accounting Standards Board (“FASB”), Statement of Financial Accounting Concepts No. 2 “Qualitative Characteristics of Accounting Information” indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the condensed consolidated financial statements for the quarter ended March 31, 2022 and to the condensed consolidated balance sheet as of June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to these periods for comparative purposes. The adjustments did not change the Company’s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations. ​ The condensed consolidated financial statements as of and for the three and nine months ended March 31, 2022 have been adjusted as shown in the following tables. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liabilities ​ $ 211 ​ $ (218) ​ $ (7) Total other (expense) income ​ $ 348 ​ $ (218) ​ $ 130 Loss before income tax ​ $ (53,073) ​ $ (218) ​ $ (53,291) Net loss ​ $ (53,073) ​ $ (218) ​ $ (53,291) Basic and diluted net loss per common share ​ $ (35.80) ​ $ (0.10) ​ $ (35.90) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Issuance of common stock, net of issuance cost ​ $ 7,034 ​ $ (3,178) ​ $ 3,856 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss by segment ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment ​ $ (52,311) ​ $ (218) ​ $ (52,529) Consumer Health Segment ​ ​ (762) ​ ​ — ​ ​ (762) Consolidated net loss ​ $ (53,073) ​ $ (218) ​ $ (53,291) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liabilities ​ $ 211 ​ $ (218) ​ $ (7) Total other (expense) income ​ $ 384 ​ $ (218) ​ $ 166 Loss before income tax ​ $ (92,582) ​ $ (218) ​ $ (92,800) Net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) Basic and diluted net loss per common share ​ $ (68.00) ​ $ (0.13) ​ $ (68.13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flow data ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) Gain on derivative warrant liabilities ​ $ (211) ​ $ 218 ​ $ 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss by segment ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment ​ $ (88,359) ​ $ (218) ​ $ (88,577) Consumer Health Segment ​ ​ (4,113) ​ ​ — ​ ​ (4,113) Consolidated net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional paid-in capital ​ $ 331,915 ​ $ (3,178) ​ $ 328,737 Accumulated deficit ​ ​ (270,771) ​ ​ (218) ​ ​ (270,989) Total stockholders’ equity ​ $ 61,144 ​ $ (3,396) ​ $ 57,748 ​ The consolidated balance sheet and the consolidated statement of stockholders’ equity as of June 30, 2022 have been adjusted as shown in the table below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Derivative warrant liabilities ​ $ — ​ $ 1,796 ​ $ 1,796 Total liabilities ​ $ 91,531 ​ $ 1,784 ​ $ 93,315 Additional paid-in capital ​ $ 334,560 ​ $ (3,174) ​ $ 331,386 Accumulated deficit ​ $ (288,472) ​ $ 1,394 ​ $ (287,078) Total stockholders’ equity ​ $ 46,092 ​ $ (1,784) ​ $ 44,308 ​
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.
Income Taxes	Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and nine months ended March 31, 2023. An ownership change (generally a 50% change in equity ownership over a three-year period) could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. The Company believes that previous acquisitions, financing transactions, and equity ownership changes in the past five years may have caused a limitation on its ability to use the pre-acquisition net operating loss carryovers. The ownership change scenario could result in increased future tax liability. The Company is in the process of analyzing the impact of any possible ownership change result of which may be a change to the Company’s net deferred tax asset or liability position.
Impairment of Other Intangibles Assets	Impairment of Other Intangibles Assets Acquired in-process research and development (“IPR&D) is an intangible asset classified as an indefinite-lived asset until the completion or abandonment of the associated research and development (“R&D”) effort. In periods after the acquisition of IPR&D, the Company may (1) continue internal R&D efforts associated with the acquired assets or collaborate with another party in R&D efforts; (2) dispose of the assets through a sale; (3) out-license the assets; (4) temporarily postpone further development; or (5) abandon R&D efforts. IPR&D may be subject to different subsequent accounting treatment depending on the course of action chosen by the Company with respect to the asset. If the Company changes strategies related to the IPR&D the asset could potentially be impaired (see Note —7 Goodwill and Other Intangible Assets).
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recent Adopted Accounting Pronouncements Reference Rate Reform. , Reference Rate Reform (Topic 848): “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” Earnings Per Share. In May 2021, the FASB issued ASU 2021-04, “ Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ”. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on its condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” anticipate the application of ASU 2016-13 will have a material impact on the Company’s condensed consolidated financial position or results of operations. For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. There have been no significant changes to the Company’s significant accounting policies during the nine months ended March 31, 2023.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of the impact of the immaterial correction of an error	The condensed consolidated financial statements as of and for the three and nine months ended March 31, 2022 have been adjusted as shown in the following tables. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liabilities ​ $ 211 ​ $ (218) ​ $ (7) Total other (expense) income ​ $ 348 ​ $ (218) ​ $ 130 Loss before income tax ​ $ (53,073) ​ $ (218) ​ $ (53,291) Net loss ​ $ (53,073) ​ $ (218) ​ $ (53,291) Basic and diluted net loss per common share ​ $ (35.80) ​ $ (0.10) ​ $ (35.90) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Issuance of common stock, net of issuance cost ​ $ 7,034 ​ $ (3,178) ​ $ 3,856 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss by segment ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment ​ $ (52,311) ​ $ (218) ​ $ (52,529) Consumer Health Segment ​ ​ (762) ​ ​ — ​ ​ (762) Consolidated net loss ​ $ (53,073) ​ $ (218) ​ $ (53,291) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liabilities ​ $ 211 ​ $ (218) ​ $ (7) Total other (expense) income ​ $ 384 ​ $ (218) ​ $ 166 Loss before income tax ​ $ (92,582) ​ $ (218) ​ $ (92,800) Net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) Basic and diluted net loss per common share ​ $ (68.00) ​ $ (0.13) ​ $ (68.13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flow data ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) Gain on derivative warrant liabilities ​ $ (211) ​ $ 218 ​ $ 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss by segment ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment ​ $ (88,359) ​ $ (218) ​ $ (88,577) Consumer Health Segment ​ ​ (4,113) ​ ​ — ​ ​ (4,113) Consolidated net loss ​ $ (92,472) ​ $ (218) ​ $ (92,690) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional paid-in capital ​ $ 331,915 ​ $ (3,178) ​ $ 328,737 Accumulated deficit ​ ​ (270,771) ​ ​ (218) ​ ​ (270,989) Total stockholders’ equity ​ $ 61,144 ​ $ (3,396) ​ $ 57,748 ​ The consolidated balance sheet and the consolidated statement of stockholders’ equity as of June 30, 2022 have been adjusted as shown in the table below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Derivative warrant liabilities ​ $ — ​ $ 1,796 ​ $ 1,796 Total liabilities ​ $ 91,531 ​ $ 1,784 ​ $ 93,315 Additional paid-in capital ​ $ 334,560 ​ $ (3,174) ​ $ 331,386 Accumulated deficit ​ $ (288,472) ​ $ 1,394 ​ $ (287,078) Total stockholders’ equity ​ $ 46,092 ​ $ (1,784) ​ $ 44,308

Revenues from Contracts with _2

Revenues from Contracts with Customers (Tables)	9 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 ​ ​ (In thousands) ​ Rx Segment ​ $ 13,805 ​ $ 13,862 ​ $ 50,486 ​ $ 42,388 ​ Consumer Health Segment ​ ​ 8,928 ​ ​ 10,337 ​ ​ 26,181 ​ ​ 26,833 ​ Consolidated revenue $ 22,733 $ 24,199 $ 76,667 $ 69,221 ​

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ (In thousands) Raw materials $ 2,223 $ 1,814 Work in process ​ ​ 2,817 ​ ​ 1,838 Finished goods ​ 8,597 ​ 7,197 Inventory ​ $ 13,637 ​ $ 10,849

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,449 $ 2,487 Leasehold improvements 1,003 ​ 999 Office equipment, furniture and other 1,128 ​ 1,128 Lab equipment 832 ​ 832 Property and equipment, gross ​ ​ 5,412 ​ ​ 5,446 Less accumulated depreciation and amortization ​ ​ (3,384) ​ ​ (2,421) Property and equipment, net $ 2,028 ​ $ 3,025 ​ ​

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of components of lease expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ ​ March 31, ​ March 31, ​ ​ ​ 2023 2022 2023 2022 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 360 ​ $ 316 ​ $ 1,076 ​ $ 942 Operating expenses Short-term lease cost 27 ​ 65 71 ​ 130 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets 14 ​ 18 51 ​ 55 Cost of sales Interest on lease liabilities ​ ​ 2 ​ ​ 3 ​ ​ 7 ​ ​ 11 ​ Other (expense), net Total net lease cost $ 403 ​ $ 402 $ 1,205 ​ $ 1,138 ​ ​
Schedule of balance sheet information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, Balance Sheet Classification ​ ​ 2023 ​ 2022 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 2,367 ​ $ 3,271 Operating lease right-of-use asset Finance lease assets ​ ​ 174 ​ 256 Property and equipment, net Total leased assets ​ $ 2,541 ​ $ 3,527 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,252 ​ $ 1,227 ​ Other current liabilities Finance leases ​ ​ 91 ​ ​ 96 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 1,154 ​ ​ 2,090 ​ Other non-current liabilities Finance leases ​ ​ 15 ​ ​ 84 ​ Debt, net of current portion Total lease liabilities ​ $ 2,512 ​ $ 3,497 ​ ​ ​ ​
Schedule of remaining lease term and discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 1.94 ​ ​ 2.63 ​ Finance lease assets ​ 1.12 ​ ​ 1.73 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.68 % ​ 7.48 % Finance lease assets ​ ​ 6.54 % ​ 6.43 % ​ ​
Schedule of supplemental cash flow information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, ​ 2023 2022 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows - operating leases ​ $ 1,076 ​ $ 942 Operating cash flows - finance leases ​ $ 7 ​ $ 12 Financing cash flows - finance leases ​ $ 73 ​ $ 76 ​ ​
Schedule of maturities of future minimum lease payments, operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 360 ​ $ 23 2024 ​ ​ 1,379 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 2,624 ​ ​ 110 Less: Imputed interest ​ ​ (218) ​ ​ (4) Lease liabilities ​ $ 2,406 ​ $ 106
Schedule of maturities of future minimum lease payments, finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 360 ​ $ 23 2024 ​ ​ 1,379 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 2,624 ​ ​ 110 Less: Imputed interest ​ ​ (218) ​ ​ (4) Lease liabilities ​ $ 2,406 ​ $ 106

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ ​ 45,400 ​ ​ (10,077) ​ ​ (3,224) ​ ​ 32,099 11.55 Acquired technology right ​ ​ 30,200 ​ ​ (3,610) ​ ​ — ​ ​ 26,590 ​ 15.00 Acquired product distribution rights ​ 11,354 ​ (4,407) ​ (2,172) ​ 4,775 6.85 ​ ​ ​ 86,954 ​ ​ (18,094) ​ ​ (5,396) ​ ​ 63,464 ​ 12.64 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 89,554 ​ $ (18,094) ​ $ (7,996) ​ $ 63,464 12.64 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 45,400 ​ $ (7,667) ​ $ (3,224) ​ $ 34,509 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ 11,354 ​ (3,581) ​ (2,172) ​ 5,601 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 13.35 ​ ​
Schedule of Indefinite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ ​ 45,400 ​ ​ (10,077) ​ ​ (3,224) ​ ​ 32,099 11.55 Acquired technology right ​ ​ 30,200 ​ ​ (3,610) ​ ​ — ​ ​ 26,590 ​ 15.00 Acquired product distribution rights ​ 11,354 ​ (4,407) ​ (2,172) ​ 4,775 6.85 ​ ​ ​ 86,954 ​ ​ (18,094) ​ ​ (5,396) ​ ​ 63,464 ​ 12.64 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 89,554 ​ $ (18,094) ​ $ (7,996) ​ $ 63,464 12.64 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 45,400 ​ $ (7,667) ​ $ (3,224) ​ $ 34,509 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ 11,354 ​ (3,581) ​ (2,172) ​ 5,601 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 13.35 ​ ​ ​
Schedule of future amortization expense	​ ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 1,518 2024 ​ ​ 6,074 2025 ​ ​ 5,934 2026 ​ ​ 5,683 2027 ​ ​ 5,653 2028 ​ ​ 5,553 Thereafter ​ ​ 33,049 Total future amortization expense ​ $ 63,464 ​ ​

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Mar. 31, 2023
Accrued Liabilities, Current [Abstract]
Schedule of Accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Accrued savings offers ​ $ 18,370 ​ $ 12,711 Accrued program liabilities ​ ​ 10,287 ​ ​ 9,468 Accrued customer and product related fees ​ ​ 6,379 ​ ​ 7,817 Product return reserve ​ 4,708 ​ 5,770 Accrued employee compensation ​ ​ 6,864 ​ ​ 4,765 Other accrued liabilities ​ ​ 2,977 ​ ​ 3,656 Total accrued liabilities ​ $ 49,585 ​ $ 44,187 ​ ​

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangements ​ $ 10,678 ​ $ 13,051 Operating lease liabilities ​ 2,406 ​ 3,317 Contingent value rights ​ ​ 465 ​ ​ 578 Contingent consideration ​ ​ — ​ ​ 396 Other ​ ​ 1,821 ​ ​ 815 Total other liabilities ​ ​ 15,370 ​ ​ 18,157 Less: current portion ​ ​ (7,450) ​ ​ (5,359) Total other liabilities, noncurrent ​ $ 7,920 ​ $ 12,798 ​ ​

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of long term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 ​ ​ 638 Unamortized discount and issuance costs ​ ​ (1,053) ​ ​ (1,443) Financing leases, maturing through May 2024 ​ ​ 106 ​ ​ 180 Total debt ​ ​ 14,691 ​ ​ 14,375 Less: current portion ​ ​ (3,305) ​ ​ (96) Non-current portion of debt ​ $ 11,386 ​ $ 14,279 ​
Schedule of future principal payments of long term debt	​ ​ ​ ​ ​ ​ March 31, ​ ​ (In thousands) 2023 (remaining 3 months) ​ $ 91 2024 ​ ​ 3,230 2025 ​ ​ 12,423 Future principal payments ​ ​ 15,744 Less unamortized discount and issuance costs ​ ​ (1,053) Less current portion ​ ​ (3,305) Non-current portion of debt ​ $ 11,386

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at March 31, 2023 ​ Fair Value at March 31, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration $ — $ — $ — $ — CVR liability ​ 465 ​ — ​ — ​ 465 Derivative warrant liabilities ​ ​ 1,582 ​ — ​ — ​ 1,582 Total ​ $ 2,047 $ — $ — ​ $ 2,047 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 396 $ — $ — $ 396 CVR liability ​ ​ 578 ​ — ​ — ​ 578 Derivative warrant liabilities ​ ​ 1,796 ​ ​ — ​ ​ — ​ ​ 1,796 Total ​ $ 2,770 $ — $ — ​ $ 2,770 ​ ​
Schedule of changes in Level 3 inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent ​ ​ Derivative ​ Fixed Payment ​ ​ Liability ​ Consideration ​ ​ Warrant Liabilities ​ Arrangement ​ ​ (In thousands) Balance as of June 30, 2022 $ 578 ​ $ 396 ​ $ 1,796 ​ $ 13,051 Included in earnings ​ (113) ​ ​ (391) ​ ​ (6,167) ​ ​ 1,202 Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ ​ ​ ​ Issues — ​ — ​ 5,953 ​ — Settlements — ​ (5) ​ — ​ (3,575) Balance as of March 31, 2023 $ 465 ​ $ — ​ $ 1,582 ​ $ 10,678 ​
Schedule of significant assumptions used in valuation	Significant assumptions used in valuing CVRs were as follows: ​ ​ ​ ​ ​ ​ March 31, ​ 2023 Leveraged Beta 0.82 ​ Market risk premium ​ 6.35 % Risk-free interest rate ​ 4.79 % Discount ​ 21.25 % Company specific discount 10.00 % ​ ​ ​ Significant assumptions used in valuing ​ ​ ​ ​ ​ ​ August 9, ​ 2022 Expected volatility 89.89 % Equivalent term (years) ​ 4.11 ​ Risk-free rate ​ 3.09 % Dividend yield ​ 0.00 % ​ valuing ​ ​ ​ ​ ​ ​ March 31, ​ 2023 Expected volatility 75.51 % Equivalent term (years) ​ 3.84 - 4.44 ​ Risk-free rate ​ 3.65 - 3.73 % Dividend yield ​ 0.00 % ​ ​

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 3,899 ​ $ 209.70 7.77 Granted 49,212 ​ ​ 4.00 Forfeited/Cancelled (152) ​ ​ 126.84 Expired (175) ​ ​ 131.45 Outstanding at March 31, 2023 52,784 ​ $ 18.42 9.31 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at March 31, 2023 2,920 ​ $ 227.28 6.44 ​ ​
Restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 80,373 ​ $ 148.91 Granted 6,825 ​ ​ 3.79 Vested (36,695) ​ ​ 135.41 Forfeited/Cancelled ​ (6,689) ​ ​ 135.66 Unvested at March 31, 2023 43,814 ​ $ 139.63 ​ ​
Restricted stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 8,500 ​ $ 25.88 Vested (2,580) ​ ​ 26.85 Unvested at March 31, 2023 5,920 ​ $ 25.42 ​ ​
Stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2023 2022 ​ 2023 2022 ​ ​ (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales ​ $ 4 ​ $ 7 ​ $ 12 ​ $ 24 Research and development ​ ​ 2 ​ ​ 73 ​ ​ 25 ​ ​ 467 Selling and marketing ​ ​ 3 ​ ​ 23 ​ ​ 9 ​ ​ 51 General and administrative ​ 893 ​ 1,167 ​ 5,100 ​ 3,476 Total stock-based compensation expense ​ $ 902 ​ $ 1,270 ​ $ 5,146 ​ $ 4,018

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 433,174 ​ $ 92.60 4.73 Warrants issued 1,353,047 ​ 3.28 5.00 Warrants exercised ​ (87,500) ​ ​ 0.02 ​ 5.00 Warrants expired (17,414) ​ 1,200.77 — Outstanding March 31, 2023 1,681,307 ​ $ 13.41 4.30

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Antidilutive securities excluded from the computation of earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ 2023 2022 Warrants to purchase common stock - liability classified ​ ​ 1,642,235 377,893 Warrant to purchase common stock - equity classified ​ ​ 39,072 56,486 Employee stock options ​ ​ 52,784 4,193 Employee unvested restricted stock ​ ​ 48,818 106,874 Employee unvested restricted stock units ​ ​ ​ 5,920 ​ 7,724 Total ​ ​ ​ 1,788,829 553,170

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of segment financial information, consolidated revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2023 2022 ​ 2023 2022 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ ​ ​ ​ Rx Segment ​ $ 13,805 ​ $ 13,862 ​ $ 50,486 ​ $ 42,388 Consumer Health Segment ​ 8,928 ​ 10,337 ​ 26,181 ​ 26,833 Consolidated revenue ​ $ 22,733 ​ $ 24,199 ​ $ 76,667 ​ $ 69,221 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated net loss: ​ ​ ​ ​ Rx Segment ​ $ (5,777) ​ $ (52,529) ​ $ (10,931) ​ $ (88,577) Consumer Health Segment ​ (1,423) ​ (762) ​ (3,663) ​ (4,113) Consolidated net loss ​ $ (7,200) ​ $ (53,291) ​ $ (14,594) ​ $ (92,690) ​
Schedule of segment financial information, consolidated net loss	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2023 2022 ​ 2023 2022 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ ​ ​ ​ Rx Segment ​ $ 13,805 ​ $ 13,862 ​ $ 50,486 ​ $ 42,388 Consumer Health Segment ​ 8,928 ​ 10,337 ​ 26,181 ​ 26,833 Consolidated revenue ​ $ 22,733 ​ $ 24,199 ​ $ 76,667 ​ $ 69,221 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated net loss: ​ ​ ​ ​ Rx Segment ​ $ (5,777) ​ $ (52,529) ​ $ (10,931) ​ $ (88,577) Consumer Health Segment ​ (1,423) ​ (762) ​ (3,663) ​ (4,113) Consolidated net loss ​ $ (7,200) ​ $ (53,291) ​ $ (14,594) ​ $ (92,690) ​
Schedule of segment financial information, total assets	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Total assets: ​ ​ ​ ​ ​ ​ Rx Segment ​ $ 131,982 ​ $ 121,377 Consumer Health Segment ​ 15,234 ​ 16,246 Consolidated assets ​ $ 147,216 ​ $ 137,623

Nature of Business, Financial_2

Nature of Business, Financial Condition, Basis of Presentation - Segments (Details) - segment	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2	2	2

Nature of Business, Financial_3

Nature of Business, Financial Condition, Basis of Presentation - Reverse Stock Split (Details)	Jan. 06, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split, conversion ratio	0.05

Nature of Business, Financial_4

Nature of Business, Financial Condition, Basis of Presentation - Product Information (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2023 item	Mar. 31, 2022 item	Mar. 31, 2023 item product	Mar. 31, 2022 item
Consumer Health Portfolio | Minimum
Disaggregation of Revenue [Line Items]
Number of products | product			20
Rx
Disaggregation of Revenue [Line Items]
Number of product portfolios | item	2	2	2	2

Nature of Business, Financial_5

Nature of Business, Financial Condition, Basis of Presentation - General Information (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, cash equivalents and restricted cash	$ 19,179			$ 27,613			$ 19,179	$ 27,613	$ 19,360	$ 49,901
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	34,043						34,043		21,712
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	(7,200)	$ (6,693)	$ (701)	(53,291)	$ (11,548)	$ (27,851)	(14,594)	(92,690)
Retained Earnings (Accumulated Deficit) [Abstract]
Accumulated deficit	$ (301,672)			$ (270,989)			(301,672)	(270,989)	$ (287,078)
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash used in operations							$ (14,494)	$ (21,728)

Nature of Business, Financial_6

Nature of Business, Financial Condition, Basis of Presentation - Stock Offerings (Details) - USD ($) $ in Thousands		9 Months Ended
	Aug. 11, 2022	Mar. 31, 2023	Mar. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of common stock and warrants, net of issuance costs		$ 13,012	$ 12,700
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,075,290
Proceeds from issuance of common stock and warrants	$ 10,000
Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)		699,929
Proceeds from issuance of common stock, gross		$ 3,000
Commissions (as a percent)		3%

Nature of Business, Financial_7

Nature of Business, Financial Condition, Basis of Presentation - Warrants (Details)	Aug. 11, 2022 shares
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	87,500
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,265,547

Nature of Business, Financial_8

Nature of Business, Financial Condition, Basis of Presentation - Going Concern (Details)	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern, within One Year	true

Significant Accounting Polici_4

Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain (loss) on derivative warrant liabilities	$ 2,573			$ (7)			$ 6,167	$ (7)
Total other (expense) income	1,358			130			2,640	166
Loss before income tax	(7,200)			(53,291)			(14,594)	(92,800)
Net loss	$ (7,200)	$ (6,693)	$ (701)	$ (53,291)	$ (11,548)	$ (27,851)	$ (14,594)	$ (92,690)
Basic net loss per common share (in dollars per share)	$ (1.93)			$ (35.90)			$ (4.71)	$ (68.13)
Diluted net loss per common share (in dollars per share)	$ (1.93)			$ (35.90)			$ (4.71)	$ (68.13)
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain (loss) on derivative warrant liabilities				$ 211				$ 211
Total other (expense) income				348				384
Loss before income tax				(53,073)				(92,582)
Net loss				$ (53,073)				$ (92,472)
Basic net loss per common share (in dollars per share)				$ (35.80)				$ (68)
Diluted net loss per common share (in dollars per share)				$ (35.80)				$ (68)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain (loss) on derivative warrant liabilities				$ (218)				$ (218)
Total other (expense) income				(218)				(218)
Loss before income tax				(218)				(218)
Net loss				$ (218)				$ (218)
Basic net loss per common share (in dollars per share)				$ (0.10)				$ (0.13)
Diluted net loss per common share (in dollars per share)				$ (0.10)				$ (0.13)

Significant Accounting Polici_5

Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of common stock, net of issuance costs	$ 1,393	$ 1,095	$ 3,564	$ 3,856	$ 4,355	$ 270
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of common stock, net of issuance costs				7,034
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of common stock, net of issuance costs				$ (3,178)

Significant Accounting Polici_6

Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss			$ (14,594)	$ (92,690)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
(Gain) loss on derivative warrant liabilities	$ (2,573)	$ 7	$ (6,167)	7
Previously Reported
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss				(92,472)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
(Gain) loss on derivative warrant liabilities		(211)		(211)
Revision of Prior Period, Error Correction, Adjustment
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss				(218)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
(Gain) loss on derivative warrant liabilities		$ 218		$ 218

Significant Accounting Polici_7

Significant Accounting Policies - Previously Reported Financial Statements - Net Income (Loss) by Segment (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	$ (7,200)	$ (6,693)	$ (701)	$ (53,291)	$ (11,548)	$ (27,851)	$ (14,594)	$ (92,690)
Rx
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	(5,777)			(52,529)			(10,931)	(88,577)
Consumer Health
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	$ (1,423)			(762)			$ (3,663)	(4,113)
Previously Reported
Net Income (Loss) Attributable to Parent [Abstract]
Net loss				(53,073)				(92,472)
Previously Reported | Rx
Net Income (Loss) Attributable to Parent [Abstract]
Net loss				(52,311)				(88,359)
Previously Reported | Consumer Health
Net Income (Loss) Attributable to Parent [Abstract]
Net loss				(762)				(4,113)
Revision of Prior Period, Error Correction, Adjustment
Net Income (Loss) Attributable to Parent [Abstract]
Net loss				(218)				(218)
Revision of Prior Period, Error Correction, Adjustment | Rx
Net Income (Loss) Attributable to Parent [Abstract]
Net loss				$ (218)				$ (218)

Significant Accounting Polici_8

Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Derivative warrant liabilities	$ 1,582			$ 1,796
Total liabilities	106,304			93,315
Additional paid-in capital	342,584			331,386	$ 328,737
Accumulated deficit	(301,672)			(287,078)	(270,989)
Total stockholders' equity	$ 40,912	$ 45,817	$ 48,348	44,308	57,748	$ 105,536	$ 111,500	$ 137,568
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total liabilities				91,531
Additional paid-in capital				334,560	331,915
Accumulated deficit				(288,472)	(270,771)
Total stockholders' equity				46,092	61,144
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Derivative warrant liabilities				1,796
Total liabilities				1,784
Additional paid-in capital				(3,174)	(3,178)
Accumulated deficit				1,394	(218)
Total stockholders' equity				$ (1,784)	$ (3,396)

Significant Accounting Polici_9

Significant Accounting Policies - Warrants (Details)	Mar. 31, 2023	Aug. 09, 2022
Accounting Policies [Abstract]
Derivative Liability, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember

Significant Accounting Polic_10

Significant Accounting Policies - Recent Adopted Accounting Pronouncements (Details)	Mar. 31, 2023
Accounting Standards Update 2020-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jul. 01, 2022
Accounting Standards Update 2021-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false

Revenues from Contracts with _3

Revenues from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 22,733	$ 24,199	$ 76,667	$ 69,221
Rx
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	13,805	13,862	50,486	42,388
Consumer Health
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 8,928	$ 10,337	$ 26,181	$ 26,833

Inventories - General Informati

Inventories - General Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Production Related Impairments or Charges [Abstract]
Inventory write-down and impairment	$ 0.1	$ 2	$ 0.2	$ 2.4

Inventories - Tabular Disclosur

Inventories - Tabular Disclosure (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Inventory, Net [Abstract]
Raw materials	$ 2,223	$ 1,814
Work in process	2,817	1,838
Finished goods	8,597	7,197
Inventory, net	$ 13,637	$ 10,849

Property and Equipment - Tabula

Property and Equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 5,412	$ 5,446
Less accumulated depreciation and amortization	(3,384)	(2,421)
Property and equipment, net	2,028	3,025
Manufacturing Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	2,449	2,487
Leasehold Improvements
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	1,003	999
Office Equipment, Furniture and Other
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	1,128	1,128
Lab Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 832	$ 832

Property and Equipment - Deprec

Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Depreciation, Depletion and Amortization [Abstract]
Depreciation expense	$ 0.3	$ 0.5	$ 1	$ 1.3

Leases - Net Lease Cost (Detail

Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Lease, Cost [Abstract]
Operating lease cost	$ 360	$ 316	$ 1,076	$ 942
Short-term lease cost	27	65	71	130
Amortization of leased assets	14	18	51	55
Interest on lease liabilities	2	3	7	11
Total net lease cost	$ 403	$ 402	$ 1,205	$ 1,138

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 2,367	$ 3,271
Finance lease assets	$ 174	$ 256
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property and equipment, net	Property and equipment, net
Total leased assets	$ 2,541	$ 3,527
Current portion of operating lease liabilities	1,252	1,227
Finance leases, current	$ 91	$ 96
Finance Lease, Liability, Current, Statement of Financial Position	Current portion of debt	Current portion of debt
Operating lease liabilities, net of current portion	$ 1,154	$ 2,090
Finance leases, long-term	$ 15	$ 84
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Debt, net of current portion	Debt, net of current portion
Total lease liabilities	$ 2,512	$ 3,497

Leases - Remaining Lease Term a

Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)	Mar. 31, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
Operating lease assets, weighted-average remaining lease term	1 year 11 months 8 days	2 years 7 months 17 days
Finance lease assets, weighted-average remaining lease term	1 year 1 month 13 days	1 year 8 months 23 days
Operating lease assets, weighted-average discount rate	7.68%	7.48%
Finance lease assets, weighted-average discount rate	6.54%	6.43%

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows - operating leases	$ 1,076	$ 942
Cash Flow, Investing Activities, Lessee [Abstract]
Operating cash flows - finance leases	7	12
Cash Flow, Financing Activities, Lessee [Abstract]
Financing cash flows - finance leases	$ 73	$ 76

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023 (remaining 6 months)	$ 360
2024	1,379
2025	749
2026	90
2027	46
Total lease payments	$ 2,624

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 2,624
Less: Imputed interest	(218)
Lease liabilities	$ 2,406	$ 3,317

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2023 (remaining 6 months)	$ 23
2024	87
Total lease payments	$ 110

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 110
Less: Imputed interest	(4)
Lease liabilities	$ 106	$ 180

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Intangible Assets Impairment (Excluding Goodwill) (Details) $ in Millions	9 Months Ended
	Mar. 31, 2023 USD ($)
Asset Impairment Charges [Abstract]
Impairment of intangible assets, indefinite-lived (excluding goodwill)	$ 2.6

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 86,954	$ 91,620
Accumulated amortization	(18,094)	(16,530)
Finite-lived intangible assets, accumulated impairment	(5,396)	(7,058)
Finite-lived intangible assets, net	63,464	68,032
Product Technology Right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	45,400	45,400
Accumulated amortization	(10,077)	(7,667)
Finite-lived intangible assets, accumulated impairment	(3,224)	(3,224)
Finite-lived intangible assets, net	32,099	34,509
Developed Technology Rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	30,200	30,200
Accumulated amortization	(3,610)	(2,278)
Finite-lived intangible assets, net	26,590	27,922
Product Distribution Rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	11,354	11,354
Accumulated amortization	(4,407)	(3,581)
Finite-lived intangible assets, accumulated impairment	(2,172)	(2,172)
Finite-lived intangible assets, net	$ 4,775	5,601
Other Intangible Assets
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount		4,666
Accumulated amortization		(3,004)
Finite-lived intangible assets, accumulated impairment		$ (1,662)

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details) - Weighted Average	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	12 years 7 months 20 days	13 years 4 months 6 days
Product Technology Right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	11 years 6 months 18 days	12 years 3 months 29 days
Developed Technology Rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	15 years	15 years 9 months
Product Distribution Rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	6 years 10 months 6 days	7 years 7 months 6 days

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]
Indefinite-lived intangible assets, before accumulated impairment	$ 2,600
Indefinite-lived intangible assets, accumulated impairment	$ (2,600)
Indefinite-lived intangible assets		$ 2,600

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 86,954	$ 91,620
Indefinite-lived intangible assets		2,600
Intangible assets, gross carrying amount	89,554	94,220
Accumulated amortization	(18,094)	(16,530)
Finite-lived intangible assets, accumulated impairment	(5,396)	(7,058)
Indefinite-lived intangible assets, accumulated impairment	(2,600)
Impairment	(7,996)	(7,058)
Intangible assets, net carrying amount	$ 63,464	$ 70,632

Goodwill and Other Intangible_8

Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023 (remaining 6 months)	$ 1,518
2024	6,074
2025	5,934
2026	5,683
2027	5,653
2028	5,553
Thereafter	33,049
Finite-lived intangible assets, net	$ 63,464	$ 68,032

Goodwill and Other Intangible_9

Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)	9 Months Ended
	Mar. 31, 2023
Supply and Distribution Agreement, Tris Pharma, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years

Goodwill and Other Intangibl_10

Goodwill and Other Intangible Assets - Estimated Useful Life (Details)	9 Months Ended
	Mar. 31, 2023
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	20 years
Product Technology Right | Attention Deficit Hyperactivity Disorder Portfolio
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	17 years

Goodwill and Other Intangibl_11

Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details) - Innovus Pharmaceuticals, Inc	1 Months Ended
	Feb. 29, 2020 product item
Business Acquisition [Line Items]
Number of products acquired | product	35
Number of registered trademarks and or patent rights and customer lists acquired | item	300

Goodwill and Other Intangibl_12

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Amortization [Abstract]
Amortization expense	$ 1.5	$ 2	$ 4.6	$ 6.1

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Accrued savings offers	$ 18,370	$ 12,711
Accrued program liabilities	10,287	9,468
Accrued customer and product related fees	6,379	7,817
Product return reserve	4,708	5,770
Accrued employee compensation	6,864	4,765
Other accrued liabilities	2,977	3,656
Total accrued liabilities	$ 49,585	$ 44,187

Other Liabilities - Components

Other Liabilities - Components (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Other Liabilities, Unclassified [Abstract]
Fixed payment arrangements	$ 10,678	$ 13,051
Operating lease liabilities	2,406	3,317
Contingent value rights	465	578
Contingent consideration		396
Other	1,821	815
Total other liabilities	$ 15,370	$ 18,157

Other Liabilities - Classificat

Other Liabilities - Classification (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Other Liabilities [Abstract]
Total other liabilities	$ 15,370	$ 18,157
Less: current portion	(7,450)	(5,359)
Total other liabilities, noncurrent	$ 7,920	$ 12,798

Other Liabilities - Fixed Payme

Other Liabilities - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($)	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 10,678	$ 13,051
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number | agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									$ 15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements								$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)									15%
Fixed payment arrangements, monthly variable payment amount, minimum									$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026									$ 9,300
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements	$ 9,000
Fixed payment arrangements, current						4,000
Fixed payment arrangements, noncurrent						$ 2,400
Fixed payment arrangements, liability, reduction	8,000
Fixed payment arrangements, monthly payments, interest rate percentage, minimum (as a percent)						2.50%
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Fixed payment arrangements, current						$ 1,700
Fixed payment arrangements, noncurrent						$ 2,600
Issues, fixed payment arrangements	$ 7,600

Other Liabilities - Supply and

Other Liabilities - Supply and Distribution Agreement (Details) - 9 months ended Mar. 31, 2023 - Supply and Distribution Agreement, Tris Pharma, Inc	Total	USD ($)	item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units	70,000		70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit		$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount		2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation		3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount		$ 40,000,000

Other Liabilities - Contingent

Other Liabilities - Contingent Value Rights (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022	Feb. 29, 2020
Other Liabilities Disclosure [Abstract]
Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum	$ 5,000		$ 16,000
Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)			470,000
Contingent value rights	$ 465	$ 578

Other Liabilities - Contingen_2

Other Liabilities - Contingent Consideration - Business Combination (Details) - Innovus Pharmaceuticals, Inc - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022	Feb. 29, 2020
Business Acquisition [Line Items]
Business combination, contingent consideration, product related, milestone payable, amount			$ 200
Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)			30%
Contingent consideration	$ 0	$ 400

Other Liabilities - Contingen_3

Other Liabilities - Contingent Consideration - Other than Business Combination (Details) - USD ($) $ in Thousands	May 12, 2022	Mar. 31, 2021	Mar. 31, 2023	Jun. 30, 2022
Other Commitments [Line Items]
Other current liabilities			$ 7,450	$ 5,359
Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period	$ 8,500
Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period		$ 600
Other current liabilities		$ 50

Line of Credit (Details)

Line of Credit (Details) $ in Thousands			1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 24, 2023 USD ($)	Jan. 26, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2023 USD ($) D	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($) D	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)
Short-Term Debt [Line Items]
Payment for debt issuance costs						$ 92	$ 363
Interest expense including amortization of deferred financing costs				$ 700	$ 400	2,000	400
Short-term line of credit				$ 10,403		$ 10,403		$ 3,813
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans
Short-Term Debt [Line Items]
Maximum borrowing capacity, increase (decrease)	$ 2,000
Maximum borrowing capacity	14,500	$ 12,500	$ 25,000
Unused capacity commitment fee (as a percent)			0.50%
Debt instrument, maturity date		Jan. 26, 2025	May 11, 2022
Availability block		$ 3,500	$ 1,000
Payment for debt issuance costs	$ 10
Termination fee before 26 January 2023 (as a percent)				2%		2%
Termination fee after 26 January 2023, but before 26 January 2024 (as a percent)				1%		1%
Termination fee after 26 January 2024, but on or before 26 January 2025 (as a percent)				0.50%		0.50%
Notice period | D				5		5
Interest expense including amortization of deferred financing costs				$ 200	$ 100	$ 500	$ 400
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Short-Term Debt [Line Items]
Basis spread on variable rate (as a percent)			4.50%
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans
Short-Term Debt [Line Items]
Maximum borrowing capacity			$ 2,500
Maximum borrowing capacity, percentage of eligible accounts receivable (as a percent)			85%

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 26, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Debt Instrument [Line Items]
Debt Instrument, Interest Payment Term	18 months
Debt Instrument, Interest Payment Extension Term	6 months
Interest Only Period Further Extension Term	12 months
Debt Instrument, Term of Trailing Months Revenue	12 months
Debt Instrument Prepayment Fee Percentage	3%
Long-term, final payment fee	$ 600	$ 638		$ 638		$ 638
Loan Processing Fee				$ 400
Debt Instrument, Interest Rate, Effective Percentage		15.37%		15.37%
Interest expense including amortization of deferred financing costs		$ 700	$ 400	$ 2,000	$ 400
Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage	2%
Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage	1%
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Debt instrument, minimum variable rate before basis spread (as a percent)	3.25%
Debt instrument, basis spread on variable rate (as a percent)	7.40%
Face amount	$ 15,000

Long-term Debt - Warrants (Deta

Long-term Debt - Warrants (Details) - $ / shares	Mar. 07, 2022	Jan. 26, 2022	Oct. 25, 2022
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 25
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Mar. 07, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 24.20		$ 8.60
Class of warrant or right, number of securities called by warrants or right (in shares)	43,388
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 24.20

Long-term Debt - Composition (D

Long-term Debt - Composition (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022	Jan. 26, 2022
Debt Disclosure [Abstract]
Long-term debt, due on January 26, 2025	$ 15,000	$ 15,000
Long-term, final payment fee	638	638	$ 600
Unamortized discount	(1,053)	(1,443)
Financing leases, maturing through May 2024	106	180
Total debt	14,691	14,375
Less current portion	(3,305)	(96)
Non-current portion of debt	$ 11,386	$ 14,279

Long-term Debt - Future Princip

Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
2023	$ 91
2024	3,230
2025	12,423
Future principal payments	15,744
Less unamortized discount and issuance costs	(1,053)
Less current portion	(3,305)	$ (96)
Non-current portion of debt	$ 11,386	$ 14,279

Fair Value Considerations - Rec

Fair Value Considerations - Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration		$ 396
CVR liability	$ 465	$ 578
Derivative Liability, Statement of Financial Position	Derivative warrant liabilities	Derivative warrant liabilities
Fair Value, Recurring
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration		$ 396
CVR liability	$ 465	578
Derivative warrant liabilities	1,582	1,796
Total	2,047	2,770
Fair Value, Recurring | Fair Value, Inputs, Level 3
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration		396
CVR liability	465	578
Derivative warrant liabilities	1,582	1,796
Total	$ 2,047	$ 2,770

Fair Value Considerations - Uno

Fair Value Considerations - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2023 USD ($)
Contingent Value Rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 578
Included in earnings	$ (113)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period
Ending balance	$ 465
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	396
Included in earnings	$ (391)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period
Settlements	$ (5)
Derivative Financial Instruments, Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1,796
Included in earnings	$ (6,167)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Gain (loss) on derivative warrant liabilities
Issues	$ 5,953
Ending balance	$ 1,582

Fair Value Considerations - U_2

Fair Value Considerations - Unobservable Inputs Reconciliation, Non-recurring Basis, Liabilities (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value Disclosures [Abstract]
Beginning balance, fixed payment arrangements	$ 13,051
Included in earnings, fixed payment arrangements	1,202
Settlements, fixed payment arrangements	(3,575)
Ending balance, fixed payment arrangements	$ 10,678

Fair Value Considerations - Val

Fair Value Considerations - Valuation Assumptions (Details)	Mar. 31, 2023 Y	Aug. 09, 2022 Y
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember
Measurement Input, Leveraged Beta
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.82
Measurement Input, Market Risk Premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0635
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.7551	0.8989
Measurement Input, Expected Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		4.11
Measurement Input, Expected Term | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.84
Measurement Input, Expected Term | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.44
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0479
Derivative liability, measurement input		0.0309
Measurement Input, Risk Free Interest Rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0365
Measurement Input, Risk Free Interest Rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0373
Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.2125
Measurement Input, Discount for Lack of Marketability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.1000
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0

Commitments and Contingencies -

Commitments and Contingencies - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($)	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 10,678	$ 13,051
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number | agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements								$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, minimum									$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements	$ 9,000
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Issues, fixed payment arrangements	$ 7,600

Commitments and Contingencies_2

Commitments and Contingencies - Supply and Distribution Agreement (Details) - 9 months ended Mar. 31, 2023 - Supply and Distribution Agreement, Tris Pharma, Inc	Total	USD ($)	item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units	70,000		70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit		$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount		2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation		3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount		$ 40,000,000

Commitments and Contingencies_3

Commitments and Contingencies - Earn Out Payments (Details) $ in Thousands	Apr. 12, 2021 USD ($)
Commercial Global License Agreements, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, milestone, maximum earn-out, cash and common stock	$ 67,500
Commercial Global License Agreement, Denovo Biopharma LLC, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, license option fee	600
License agreement, escalating royalties, maximum	101,700
Commercial Global License Agreement, Johns Hopkins University, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, minimum annual royalties, low end of range	$ 20
License agreement, royalties, percentage of net product sales (as a percent)	3%
License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum	$ 1,600

Commitments and Contingencies_4

Commitments and Contingencies - Legal Proceeding (Details) $ in Millions	Mar. 31, 2023 USD ($)
Aponowicz and Paguia Class-Action Securities Litigations
Loss Contingency Accrual, Disclosures [Abstract]
Accrued for plaintiff's attorney fees	$ 0.4

Capital Structure - Common and

Capital Structure - Common and Preferred Stock (Details) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

Capital Structure - Restricted

Capital Structure - Restricted Stock (Details) - shares	Mar. 31, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	3,779,513	1,928,941
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	48,818

Capital Structure - Stock Offer

Capital Structure - Stock Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Aug. 11, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 07, 2022	Sep. 28, 2021	Jun. 04, 2021	Jun. 08, 2020
Subsidiary, Sale of Stock [Line Items]
Share price (in dollars per share)				$ 25
Proceeds from issuance of common stock and warrants, net of issuance costs		$ 13,012	$ 12,700
Shelf Registration Statement, 2020 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized							$ 100,000
Shelf registration, remaining amount available for sale		40,400
Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement
Subsidiary, Sale of Stock [Line Items]
At-the-market sales agreement, amount authorized						$ 30,000
At-the-market sales agreement, remaining amount available for sale		$ 2,000
Issuance of common stock (in shares)		699,929
Proceeds from issuance of stock, net		$ 2,900
Shelf Registration Statement, 2021 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized					$ 100,000
Shelf registration, remaining amount available for sale		$ 82,400
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,075,290
Proceeds from issuance of common stock and warrants	$ 10,000
Underwriting discounts, commissions, and other offering expenses	$ 900

Capital Structure - Warrants (D

Capital Structure - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Aug. 11, 2022	Mar. 07, 2022	Jan. 26, 2022	Mar. 31, 2022	Mar. 31, 2023	Oct. 25, 2022	Aug. 31, 2022
Class of Warrant or Right [Line Items]
Fair value of warrants as additional paid in capital				$ 379
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Mar. 07, 2022
Class of warrant or right, number of securities called by warrants or right (in shares)		43,388
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 24.20				$ 8.60
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable			Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 24.20
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Aug. 11, 2022
Class of warrant or right, offering price (in dollars per share)	$ 8.58
Fair value of warrants	$ 6,000
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.02						$ 0.001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 8.60				$ 3.30
Warrants and rights outstanding, term	5 years

Equity Incentive Plans - Genera

Equity Incentive Plans - General Information (Details) - shares	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Apr. 19, 2021	Mar. 31, 2021	Feb. 13, 2020	Jun. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	52,784	3,899
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)	5,920	8,500
Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)					250,000	150,000
Number of shares available for grant (in shares)	84,554
Aytu 2015 Plan | Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Aytu 2015 Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)	43,814	80,373
Aytu 2015 Plan | Restricted Stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Aytu 2015 Plan | Restricted Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	10 years
Aytu 2015 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Neos 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)				3,486
Number of shares available for grant (in shares)	2,579		5,272
Neos 2015 Plan | Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Neos 2015 Plan | Share-Based Payment Arrangement, Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Neos 2015 Plan | Share-Based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Neos 2015 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)				1,786

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Options (Details) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding, beginning balance (in shares)	3,899
Granted (in shares)	49,212
Forfeited/cancelled (in shares)	(152)
Expired (in shares)	(175)
Number of options outstanding, ending balance (in shares)	52,784	3,899
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding, beginning balance (in dollars per share)	$ 209.70
Granted (in dollars per share)	4
Forfeited/cancelled (in dollars per share)	126.84
Expired (in dollars per share)	131.45
Weighted average exercise price outstanding, ending balance (in dollars per share)	$ 18.42	$ 209.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life (Year)	9 years 3 months 21 days	7 years 9 months 7 days
Number of options exercisable	2,920
Weighted average exercise price exercisable (in dollars per share)	$ 227.28
Weighted average remaining contractual life in years exercisable	6 years 5 months 8 days

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock - Equity Compensation Expense (Details) $ in Thousands		3 Months Ended			9 Months Ended
	Dec. 19, 2022 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) item	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 902		$ 1,270	$ 5,146	$ 4,018
Restricted Stock | Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated unvested shares, former board members, number | item			2
Stock-based compensation expense			$ 1,500
Restricted Stock | Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stipulation of compromise and settlement, board members, percentage of 2021 grants rescinded (as a percent)	25%
Stock-based compensation expense	$ 600

Equity Incentive Plans - Rest_2

Equity Incentive Plans - Restricted Stock - Activity (Details) - Restricted Stock - Aytu 2015 Plan	9 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) | shares	80,373
Granted (in shares) | shares	6,825
Vested (in shares) | shares	(36,695)
Forfeited/Cancelled (in shares) | shares	(6,689)
Unvested outstanding, ending balance (in shares) | shares	43,814
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 148.91
Granted (in dollars per share) | $ / shares	3.79
Vested (in dollars per share) | $ / shares	135.41
Forfeited/Cancelled (in dollars per share) | $ / shares	135.66
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 139.63

Equity Incentive Plans - Rest_3

Equity Incentive Plans - Restricted Stock - Additional Information (Details) - Restricted Stock - Non-plan - shares	Jan. 17, 2022	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)		4
Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	5,000

Equity Incentive Plans - Rest_4

Equity Incentive Plans - Restricted Stock Units (Details) - Restricted Stock Units (RSUs)	9 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) | shares	8,500
Vested (in shares) | shares	(2,580)
Unvested outstanding, ending balance (in shares) | shares	5,920
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 25.88
Vested | $ / shares	26.85
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 25.42

Equity Incentive Plans - Unreco

Equity Incentive Plans - Unrecognized Compensation Costs (Details) $ in Millions	9 Months Ended
	Mar. 31, 2023 USD ($)
Unrecognized compensation costs
Unrecognized compensation costs, options	$ 0.2
Share-Based Payment Arrangement, Option
Unrecognized compensation costs
Unrecognized compensation costs, period for recognition	1 year 8 months 12 days
Restricted Stock | Aytu 2015 Plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 4.9
Unrecognized compensation costs, period for recognition	2 years 4 months 24 days
Restricted Stock | Non-plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.1
Unrecognized compensation costs, period for recognition	1 year 9 months 18 days
Restricted Stock Units (RSUs)
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.1
Unrecognized compensation costs, period for recognition	1 year 10 months 24 days

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation expense
Total share-based compensation expense	$ 902	$ 1,270	$ 5,146	$ 4,018
Cost of Sales
Stock-based compensation expense
Total share-based compensation expense	4	7	12	24
Research and Development Expense
Stock-based compensation expense
Total share-based compensation expense	2	73	25	467
Selling and Marketing Expense
Stock-based compensation expense
Total share-based compensation expense	3	23	9	51
General and Administrative Expense
Stock-based compensation expense
Total share-based compensation expense	$ 893	$ 1,167	$ 5,100	$ 3,476

Warrants - General Information

Warrants - General Information (Details)					9 Months Ended
	Jan. 06, 2023	Aug. 11, 2022 D $ / shares shares	Mar. 07, 2022 $ / shares shares	Jan. 26, 2022 $ / shares	Mar. 31, 2023 D $ / shares shares	Oct. 25, 2022 $ / shares	Aug. 31, 2022 $ / shares	Jun. 30, 2022 shares
Class of Warrant or Right [Line Items]
Stock split, conversion ratio	0.05
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants expired (in shares)					17,414
Outstanding warrants (in shares)					1,681,307			433,174
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)			43,388
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares			$ 24.20			$ 8.60
Class of warrant or right, date from which warrants or rights exercisable			Mar. 07, 2022
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares				$ 24.20
Class of warrant or right, date from which warrants or rights exercisable				Jan. 26, 2022
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Aug. 11, 2022
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)		1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares		$ 0.02					$ 0.001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)		1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares		$ 8.60			$ 3.30
Warrants and rights outstanding, term		5 years
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days) | D		5			5
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days) | D		20			20
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one		5
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share) | $ / shares		$ 2.32
Class of warrant or right, exercise price adjustment, maximum shares (in shares)		2,325,581
Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share) | $ / shares		$ 2.32

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Details) - Warrants to Purchase Common Stock - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Class of Warrant or Right [Line Items]
Outstanding, number of warrants (in shares)	433,174
Warrants issued (in shares)	1,353,047
Warrants exercised (in shares)	(87,500)
Warrants expired (in shares)	(17,414)
Outstanding, number of warrants (in shares)	1,681,307	433,174
Outstanding, weighted average remaining contractual life	4 years 3 months 18 days	4 years 8 months 23 days
Warrants issued, weighted average remaining contractual life	5 years
Warrants exercised, weighted average remaining contractual life	5 years
Weighted Average
Class of Warrant or Right [Line Items]
Outstanding, exercise price (in dollars per share)	$ 92.60
Warrants issued (in dollars per share)	3.28
Warrants exercised (in dollars per share)	0.02
Warrants expired (in dollars per share)	1,200.77
Outstanding, exercise price (in dollars per share)	$ 13.41	$ 92.60

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,788,829	553,170
Warrants to Purchase Common Stock, Liability Classified
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,642,235	377,893
Warrants to Purchase Common Stock, Equity Classified
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	39,072	56,486
Share-Based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	52,784	4,193
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	48,818	106,874
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	5,920	7,724

License Agreements (Details)

License Agreements (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2017	Feb. 29, 2016
Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum		$ 1
License Agreement, 2017, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum	$ 1

Segment Reporting - General Inf

Segment Reporting - General Information (Details) - segment	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2	2	2

Segment Reporting - Consolidate

Segment Reporting - Consolidated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenues [Abstract]
Revenue from contract with customer	$ 22,733	$ 24,199	$ 76,667	$ 69,221
Rx
Revenues [Abstract]
Revenue from contract with customer	13,805	13,862	50,486	42,388
Consumer Health
Revenues [Abstract]
Revenue from contract with customer	$ 8,928	$ 10,337	$ 26,181	$ 26,833

Segment Reporting - Consolida_2

Segment Reporting - Consolidated Net Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	$ (7,200)	$ (6,693)	$ (701)	$ (53,291)	$ (11,548)	$ (27,851)	$ (14,594)	$ (92,690)
Rx
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	(5,777)			(52,529)			(10,931)	(88,577)
Consumer Health
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	$ (1,423)			$ (762)			$ (3,663)	$ (4,113)

Segment Reporting - Total Asset

Segment Reporting - Total Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jun. 30, 2022
Assets [Abstract]
Assets	$ 147,216	$ 137,623
Rx
Assets [Abstract]
Assets	131,982	121,377
Consumer Health
Assets [Abstract]
Assets	$ 15,234	$ 16,246

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event	Apr. 27, 2023 USD ($) ft²	Apr. 01, 2024 USD ($) ft²	Jan. 01, 2024 USD ($)	May 15, 2023 USD ($)
Sublease Portion of Grand Prairie Facility, AMT Manufacturing Solutions, LLC
Lessee, Operating Sublease, Description [Abstract]
Lessee, operating sublease, expansion date, minimum written notice period	30 days
Lessee, operating sublease, security deposit, receivable	$ 90,731
Sublease Portion of Grand Prairie Facility, AMT Manufacturing Solutions, LLC | Forecast
Lessee, Operating Sublease, Description [Abstract]
Lessee, operating sublease, base rent, monthly		$ 70,686
Sublease Portion of Grand Prairie Facility, AMT Manufacturing Solutions, LLC, Initial Sublease
Lessee, Operating Sublease, Description [Abstract]
Lessee, operating sublease, area (in sq. ft.) | ft²	22,909
Sublease Portion of Grand Prairie Facility, AMT Manufacturing Solutions, LLC, Initial Sublease | Forecast
Lessee, Operating Sublease, Description [Abstract]
Lessee, operating sublease, base rent, monthly			$ 21,000	$ 20,045
Sublease Portion of Grand Prairie Facility, AMT Manufacturing Solutions, LLC, Expansion | Forecast
Lessee, Operating Sublease, Description [Abstract]
Lessee, operating sublease, area (in sq. ft.) | ft²		54,203